Oncodesign Precision Medicine (OPM) and Servier announce the signing of a strategic collaboration for the discovery of new therapeutic targets in the treatment of pancreatic cancer – La Bourse et la Vie TV

  • Identification and validation of new therapeutic targets against pancreatic cancer
  • Construction of a common Artificial Intelligence (AI) analytical platform
  • Generation and pooling of clinical and biological data, AI tools and skills in experimental pharmacology
  • Servier can initiate a partnership with OPM in Drug Discovery based on certain targets discovered thanks to this technological approach

SURESNES, France & DIJON, France–(BUSINESS WIRE)–Regulatory News:

Servier, an international pharmaceutical group, and Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign (ALONC – FR0011766229) (Paris:ALONC) specializing in precision medicine, announce a collaborative research agreement, named “STarT Pancreas”, for the identification and validation of new therapeutic targets aimed at the development of new treatments for pancreatic ductal adenocarcinoma (PDAC).

For a period of 3 years, the agreement between Oncodesign Precision Medicine and Servier provides for two stages:

  • the initial co-development that will allow the identification of targets from the generation of data based on the OncoSNIPE clinical trial® ;

  • experimental validation of discoveries resulting from artificial intelligence;

With the option for Servier to initiate alone, or within the framework of a new partnership with Oncodesign Precision Medicine, a drug discovery program for each of the targets selected by Servier.

Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be in charge of clinical research activities. Servier will finance the associated research costs. Funding for the target identification program will be provided by OPM and Servier.

Servier has an exclusive option of an exclusive worldwide license on the results of the program, which can be exercised as soon as the targets are identified. If Servier does not exercise the option, OPM recovers an exclusive option on an exclusive license on certain categories of targets. OPM will receive an initial payment of €0.5 million and a second payment of €0.5 million, no later than December 31, 2024, subject to the achievement of certain objectives, as well as other milestone payments until ‘upon validation of the entry into Phase 1 of the drug candidate(s).

Dr Philippe Genne, CEO and Founder of Oncodesign : “ We are very happy with this original collaboration with the Servier group, in the continuity of the interactions developed for more than 25 years, it is a historical partner of Oncodesign and now of OPM. This collaboration is a direct result of our investment from 2017 in AI technologies as part of the OncoSNIPE project.®. It is a highly symbolic collaboration contract for OPM which validates the interest of the technological developments carried out over the past 5 years, it will allow us to structure and strengthen our platform and our data bank with very high quality data. OPM may keep the rights to certain targets that Servier does not wish to work on. We are happy to be able to bring our innovation based on Artificial Intelligence for precision medicine. »

Dr Stéphane Gerart, Artificial Intelligence Director of Oncodesign : “ OPM’s experience in oncology and observational clinical trial management associated with Servier’s ambition will enable the implementation of an innovative program for the identification and validation of therapeutic targets by pooling our Artificial Intelligence approaches and experimental.

Dr. Walid S. Kamoun, Oncology R&D Director at Servier : “ We are delighted to initiate this collaboration with OPM, and to contribute to the development of an AI-based data analysis solution that will help us identify new therapeutic targets in pancreatic ductal adenocarcinoma, a dreaded cancer. and growing in developed countries. This partnership is in line with the Group’s strategy, which has made oncology one of its strategic priorities, targeting difficult-to-treat cancers for which treatment options are limited.. »

Dr Jean-Philippe Stephan, Director of the in vitro pharmacology research unit at Servier: “The STarT Pancreas program, co-developed with OPM, places patient data at the heart of research activities. Our goal is to establish a highly dynamic Artificial Intelligence analytical platform, which continuously adapts based on patient-derived data and experimental validation of identified targets, to accelerate precision drug discovery programs. . »

Pancreatic cancer is considered one of the most difficult cancers to treat effectively, due to its insidious symptoms and high degree of malignancy resulting in a high mortality rate. In 2018 in France, pancreatic cancer was the 9th most common cancer in men and the 7th most common cancer in women. The number of new cases in France is estimated at 14,184 per year1. Treatment needs are great, because the incidence of pancreatic cancer is increasing year by year.

About Servier

Servier is an international pharmaceutical group governed by a Foundation. Relying on a solid geographical presence and a turnover of 4.7 billion euros in 2021 achieved in 150 countries, Servier employs 21,800 people worldwide. Servier is an independent group that invests more than 20% of its originator sales in Research and Development each year. To accelerate therapeutic innovation for the benefit of patients, the Group is part of an open and collaborative innovation dynamic with academic partners, pharmaceutical groups and biotechnology companies. It also incorporates the voice of the patient at the heart of its activities, from research to support beyond medication.

A leader in cardiology, the Servier group aims to become a recognized and innovative player in oncology. Its growth is based on a constant commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immuno-inflammatory diseases. To promote access to care for all, the Servier group also offers a range of quality generic drugs covering the majority of pathologies. More information on the website: servier.com.

Follow us on social networks: LinkedIn, Facebook, Twitter, instagram

About OncoSNIPE®

OncoSNIPE is a project whose objective is the development and implementation of bioinformatics approaches using methodologies based, among other things, on artificial intelligence, statistical learning and semantic enrichment which should allow the identification and the characterization of patients resistant to anti-cancer treatments and thus guide the research and development of specific therapeutic solutions through the identification of new targets. OncoSNIPE will enable Oncodesign Precision Medicine (OPM) to generate new therapeutic research avenues for its Experimentation and Discovery activities. The project is piloted and coordinated by Oncodesign through its subsidiary OPM; it brings together the skills of 4 industrial partners with complementary and synergistic expertise and core businesses: Expert AI (Paris), Coexya (Lyon), Acobiom (Montpellier) and Oncodesign (Dijon) and 12 academic institutions

The OncoSNIPE program® aims to stratify and characterize populations of patients resistant to cancer treatments. Oncodesign thus collects clinical, biological, genetic and imaging data and samples from chemo-naïve patients suffering from triple negative breast cancer, pancreatic cancer and lung cancer during the evolution of their treatments within the framework of an observational clinical trial.

About OPM

Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign, is a technology company specializing in precision medicine. Its mission is to provide innovative therapeutic and diagnostic solutions to treat the phenomena of therapeutic resistance and metastatic evolution of cancers. The patient is at the heart of its thinking, of its truly unique innovation model, and of its investments. With a portfolio of molecules and diversified therapeutic targets, OPM is positioned as a discoverer of effective molecules against resistant and advanced cancers and other pathologies without therapeutic solution. For OPM “working together is essential”, there can be no creation of values ​​without exchange, without dialogue. The creation of value resulting for us from reciprocity, that is to say balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. More information: opm.oncodesign.com

Forward-looking statements

This document contains forward-looking statements and estimates with respect to the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “expects”, “projects”, “plans”, “seeks”, “estimates”, “may”, “wants” and “continues” and other similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the Company’s control. Accordingly, the actual results, financial conditions, performance or achievements of the Company, or industry results, may differ materially from any future results, performance or achievements as expressed or implied by such statements, forecasts and estimates Given these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of the publication of this document. The Company disclaims any obligation to update any such forward-looking statements, forecasts or estimates to reflect any change in the Company’s expectations with respect thereto, or any change in events, conditions or circumstances on which such statements, forecasts or estimates are based. , except as required by French law.

1 Pancreatic cancers: the key points – Cancer du pancréas (e-cancer.fr)

contacts

Oncodesign
Philippe Genne

Chairman and CEO

Such. : +33 (0)3 80 78 82 60

investors@oncodesign.com

NewCap
Investor Relations

Mathilde Bohin / Louis-Victor Delouvrier

Such. : +33 (0)1 44 71 94 95

oncodesign@newcap.eu

NewCap
Media Relations

Arthur Rusty

Such. : +33 (0)1 44 71 00 15

oncodesign@newcap.eu

Press contacts:

servant
Sonia Marques I Tel. +33 (0)1 55 72 40 21 I presse@servier.com



We would love to thank the author of this write-up for this incredible web content

Oncodesign Precision Medicine (OPM) and Servier announce the signing of a strategic collaboration for the discovery of new therapeutic targets in the treatment of pancreatic cancer – La Bourse et la Vie TV


Our social media profiles here , as well as other pages on related topics here.https://www.ai-magazine.com/related-pages/